Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financi... (illion and sublicense payments an...)

Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results

Date:2/5/2008

illion and sublicense

payments and royalties on product sales.

-- Achievement of multiple milestones in Dow AgroSciences collaboration.

As part of their joint Research and Commercial License Agreement the

companies achieved milestones that represent the successful

application of Sangamo's ZFP technology to the generation of specific

traits in two major crop species -- maize and canola.

-- Sangamo closed a registered direct offering to institutional

investors. In July, Sangamo sold an aggregate of 3,278,689 shares of

common stock to a group of institutional investors in a registered

direct offering, resulting in gross proceeds to the company of

approximately $30 million before fees and expenses.

-- Appointment of H. Ward Wolff as Executive Vice President and Chief

Financial Officer (CFO). In December 2007, Mr. Wolff joined

Sangamo's senior management team after serving on the Board of

Directors of the Company since June 2006. In this newly created

position, Mr. Wolff oversees the company's administrative, financial

and business development activities and operations.

-- Sangamo hosted an Investor and Analyst Briefing. On December 5,

Sangamo provided an update on its achievements in 2007, its

therapeutic programs, progress in its collaboration with Dow

AgroSciences and its objectives for 2008 during its annual Investor

and Analyst Briefing held in New York. The event was webcast and the

replay is available on Sangamo's website at

2008 Objectives

In today's conference call members of Sangamo's management team will discuss the company's plans and objectives for 2008 that include:

Therapeutic Programs

--
'/>"/>

Post Your Comments:

Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financi...(illion and sublicense payments an...),Health